Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone

Research output: Contribution to journalArticle

Abstract

IgM-associated AL amyloidosis is a rare clinical entity with distinctive clinical characteristics. Little is known on the applicability of treatment regimens designed for Waldenström's macroglobulinemia (WM) to IgM-AL amyloidosis. Bortezomib is highly effective in AL amyloidosis and the combination of rituximab, bortezomib, and dexamethasone (RBDex) has been successfully tested in WM. Starting in May 2009 we prospectively treated with RBDex 10 patients with IgM-AL amyloidosis. Hematologic response was achieved in 78% of patients, including 3 refractory to previous rituximab. Severe adverse events (grade ≥ 3) were observed in 3 cases. Treatment of IgM-AL amyloidosis with RBDex warrants further investigation in the setting of international clinical trials.

Original languageEnglish
Pages (from-to)143-145
Number of pages3
JournalClinical Lymphoma, Myeloma and Leukemia
Volume11
Issue number1
DOIs
Publication statusPublished - Feb 1 2011

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone'. Together they form a unique fingerprint.

  • Cite this